Abstract
There is a great diversity in the clinical manifestations of sickle cell anemia. Some patients have severe repetitive infarctive episodes culminating in organ failure. Others have minor and nonincapacitating problems. This review focuses on the cellular and genetic factors that may play a role in modulating the clinical effects of the sickle hemoglobin gene. Understanding the role of putative modulators of disease severity may in the future allow the introduction of novel methods of therapy.

This publication has 70 references indexed in Scilit: